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ABSTRACT
ObjectiveToobtain largescale andgeneralisabledata on
the long term predictive value of cytology and human
papillomavirus (HPV) testing for development of cervical
intraepithelial neoplasia grade 3 or cancer (CIN3+).
Design Multinational cohort study with joint database
analysis.
Setting Seven primary HPV screening studies in six
European countries.
Participants 24295 women attending cervical screening
enrolled into HPV screening trials who had at least one
cervical cytology or histopathology examination during
follow-up.
Main outcome measure Long term cumulative incidence
of CIN3+.
Results The cumulative incidence rate of CIN3+ after six
years was considerably lower among women negative for
HPV at baseline (0.27%, 95% confidence interval 0.12%
to 0.45%) than among women with negative results on
cytology (0.97%, 0.53% to 1.34%)). By comparison, the
cumulative incidence rate for women with negative
cytology results at the most commonly recommended
screening interval in Europe (three years) was 0.51%
(0.23% to 0.77%). The cumulative incidence rate among
women with negative cytology results who were positive
forHPVincreasedcontinuouslyovertime,reaching10%at
six years, whereas the rate among women with positive
cytology results who were negative for HPV remained
below 3%.
Conclusions A consistently low six year cumulative
incidence rate of CIN3+ among women negative for HPV
suggests that cervical screening strategies in which
women are screened for HPV every six years are safe and
effective.
INTRODUCTION
Cytological screening has reduced the incidence of
cervical cancer in countries with organised screening,
1
but in Europe in 1995 there were still an estimated
68000 incident cases.
2 Cytology has limited
reproducibility,
3 and both meta-analyses and pooled
analysesofcrosssectionalstudieshaveestablishedthat
tests for human papillomavirus (HPV) have higher
sensitivity than cytology in detecting high grade
cervical intraepithelial lesions (CIN)
45 and that com-
bined HPV and cytology testing has high negative
predictive values for CIN.
6-8 Cost effectivenessmodel-
ling of screening strategies, however, depends greatly
on reliable and generalisable estimates of the long-
itudinal, long term predictive values of testing. The
long term negative predictive value is the main
determinant of the safe screening interval to use, a
key factor for the cost efficiency of a screening
programme. The long term positive predictive value
is an important measure of the extent of unnecessary
proceduresinducedbyscreening,anothermajorfactor
in evaluations of cost efficiency. As low and moderate
grades of CIN often regress, predictive values to be
used for modelling should ideally use CIN grade 3 or
cancer (CIN3+) as the outcome.
9
Several randomised controlled trials are currently
being conducted to compare primary screening based
on HPV detection with conventional cytology
screening.
10-16 Data from these trials indicate that
HPV based screening results in detection of more
high grade CIN lesions (a higher sensitivity) but a
reduced specificity compared with cytology based
screening. The randomised trials found that the
increased sensitivity for CIN3+ is not merely over-
diagnosisasthereisacorrespondinglylowerincidence
of CIN3+ in the future,
11-14 further establishing the
validityofusingCIN3+asendpointinstudiesofHPV
based cervical screening.
Mostofthecohortstudiesandtherandomisedtrials,
however,haveobservedonlylimitednumbersofcases
of CIN3+ on longer term follow-up, resulting in
reduced statistical power for estimating the critical
factor for deciding the appropriate screening interval:
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at screening. Furthermore, clinical and diagnostic
practices vary between European countries, and
different studies have often used different methods
for evaluation, making meta-analyses difficult.
To obtain large scale and generalisable data on long
term predictive values for CIN3+, we obtained
primary data from seven HPV screening studies in
six EU countries, each investigating the predictive
value of primary HPV screening for future CIN3+;
assessedvariabilitybetweenstudies;andestimatedthe
overall long term predictive values for CIN3+.
METHODS
The seven prospective HPV studies supplied data to a
common database for joint statistical analysis. Table 1
provides details of the design of the seven studies,
inclusion and exclusion criteria, setting, and location.
Allstudiesusedroutinecytologyascurrentlypractised
in their country. Table 1 also describes the different
HPV tests used for each country. For all studies the
peopleexecutingeithertestwereunawareoftheresults
of the other test. Comparability and reproducibility of
the two main HPV tests used (hybrid capture II and
GP5+/6+ polymerase chain reaction) was evaluated
with κ statistics.
17 Recruitment was consecutive and
data collection prospectively planned.
Denmark
In 1993-5 women in the general population were
enrolled in a prospective cohort study of the clinical
course of HPV and cervical neoplasia. They were
interviewed and underwent a cervical smear tests for
cytologyandcervicalswabsfordetectionofHPVDNA
withhybridcaptureII.
18Eachwoman’sunique10digit
personal identification number was linked to the
national pathology data bank (a nationwide compu-
terised pathology register containing all cytological
and histological diagnoses) to allow follow-up. Data
from women with negative results on both tests were
supplied to the joint database.
Germany: Hannover and Tübingen studies
In 1999-2000 women aged ≥30 were invited to the
medical universities in Hannover or Tübingen for a
prospective cohort study (HAT trial) on HPV
screening.
6 In Hannover women were followed with
colposcopy every 6-12 months if they had a positive
result on a hybrid capture 2 test or positive cytology at
baseline. Women with negative results on both tests
underwent annual cervical smear tests and 5% were
referred for colposcopy five years later. In Tübingen,
women with negative results on both tests at baseline
were followed up with cytology and hybrid capture II
testafterfiveyears;and ifeithertestresultwaspositive
then they were referred for colposcopy.
United Kingdom
The UK study included women attending routine
screening in west London to evaluate HPV based
screening in women aged ≥35 during 1994-7.
19 DNA
analysis was initially performed with the polymerase
Table 1 |StudycharacteristicsofsevenEuropeanhumanpapillomavirus(HPV)screeningstudies
Study
No initially
screened
No
analysed* Age Entry criteria HPV test Follow-up† Histology
Germany-
Hannover
4699 4107 ≥30 No history of abnormal smear
result, CIN, or treatment for
cervicaldiseaseinpastyearand
not pregnant
HCII If cytology+ or HPV+ immediate and annual
colposcopy‡for5years.5%ofcytology−/HPV−
to colposcopy after 5 years
Blinded central
review
Germany-
Tubingen
672 670 ≥30 No history of abnormal smear
result, CIN, or treatment for
cervicaldiseaseinpastyearand
not pregnant
HCII Cytology−/HPV−tonewtestsafter5yearsandif
either positive referred to colposcopy
Blinded central
review
Sweden 6448 5671 32-38 Participating in organised
screening
GP5+/6+
PCR
Cytology−/HPV+ invited for new test >1 year
later,ifpersistentHPV+referredtocolposcopy.
Similar number of women randomly referred to
colposcopy. Database linked with regional
pathology registries
Regional pathology
labs§
Denmark 2287 2274 20-29 No current evidence of cervical
neoplasia
HCII Study data base linked with the National
Pathology Registry
Regional pathology
lab§
UK 2720 2322 ≥35 No previous cervical treatment
orabnormal smear resultwithin
past 3 years
SHARP-PCR,
HCI, HCII
SHARP-PCR+ or cytology+ referred to
colposcopy
Blinded central
review
France 17 247 7935 Noagelimits No abnormal smear result or
untreatedcervicallesioninpast
2 years. Not HIV positive
HCII If cytology−/HPV+ new tests after 6-12 months
and if persistent HPV+ referred to colposcopy.
15% cytology−/HPV− referred to colposcopy
Blinded central
review
Spain 2012 1316 Matched to
general
population
Population registry or attending
screening
HCII Follow-uptests1 and 5 yearslater.Persistently
HPV+ referred to colposcopy
Regional pathology
lab§
HCII=hybrid capture II; CIN=cervical intraepithelial neoplasia; PCR=polymerase chain reaction.
*Women with at least one follow-up cytology or histology.
†Follow-up procedures performed in addition to routine clinical practice.
‡Assessment by colposcopy.
§Blinded to HPV status.
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18,31,33,54,51,52,56,and58.Womenwithpositive
results on HPV tests or abnormal cytology were
referred for colposcopy. The samples were retro-
spectively analysed with hybrid capture I for the first
halfofthestudyandbyhybridcaptureIIforthesecond
half of the study. HPV results reported in our analyses
are based on hybrid capture results. All women were
followed up with the National Health Service compu-
terisedcall/recallsystem,which recordsallsmeartests
andtheirresults.Inaddition,allwomenwereinvitedto
a follow-up visit with HPV test and colposcopy, and
507 out of 2982 attended.
France
Women who participated in biennial or triennial
routine screening in 1997-2002 in Reims, France,
were invited to participate in a study to evaluate HPV
testing with hybrid capture II in cervical cancer
screening.
20 All women with abnormal results on
cytology were referred for colposcopy. Women with
a positive HPV test but normal cytology results were
recalled after 6-12 months for a repeat cytological
smear and HPV test. If a cytological abnormality was
found or if the woman had a persistent HPV infection
she was referred for colposcopy. Women with normal
cytology results and a negative HPV test at baseline
were followed with standard biennial or triennial
cervical screening. A random 15% of women with
negative results on both tests at baseline were also
referred for colposcopy.
Sweden
In 1997-2000 women aged 32-38 who took part in
organised cervical screening in five regions of Sweden
(Gothenburg, Malmö,S t o c k h o l m ,U m e å,a n d
Uppsala) were invited to participate in a randomised
population based trial of primary HPV screening with
generalprimerGP5+/6+polymerasechainreaction.
21
In the intervention arm, women with a positive HPV
testwereinvitedforasecondcytologyandHPVtestat
least a year later, together with a similar number of
women randomly selected from the control arm.
Women with persistent HPV infection, as well as a
similar number of women from the control arm, were
invited for colposcopy.
21 Women with abnormal
cytology were referred for colposcopy in accordance
with established clinical algorithms. We included all
women in the intervention arm and the randomly
selected women from the control arm. All study
participants were followed by registry linkages with
comprehensiveregionalcytologyandpathologyregis-
tries by using unique personal identification numbers.
Spain
In 1997-2001 women randomly selected from the
generalpopulationofthe Barcelonametropolitanarea
or who were attending one of nine family planning
clinics for routine screening were enrolled.
22 Both
enrolmentstrategiesperformedfrequencymatchingto
the underlying general population. The study esti-
mated the incidence and prevalence of genital HPV
infection and evaluated the predictive value of
cytology and HPV testing for future CIN at one and
five years’ follow-up. HPV testing was done with
hybridcaptureII.Womenfromthegeneralpopulation
were referred for colposcopy if they had abnormal
cervicalcytologyorwerepersistentlypositiveforHPV
at the end of follow-up. Women from the family
planning clinics were referred for colposcopy if they
had abnormal cervical cytology or two consecutively
positive HPV test results.
Statistical analysis
From the joint cohort, we included only women with
adequate cytology and HPV tests at baseline and with
at least one follow-up cytological or histological test.
We regarded abnormal cytology as the equivalent of
atypical squamous cells of uncertain significance
(ASCUS) or worse for all the participating studies.
Womenwerefollowedupfromthedateofthebaseline
test.Incidencedependsonthenumberofpersonyears
offollow-up,and,foradiseasedetectablebyscreening,
follow-uprequires the person to have attended screen-
ing. Therefore, we censored follow-up at the date of
diagnosis of the CIN3+ lesion (CIN3 or invasive
cancer, including squamous and adenocarcinoma) or
at the last registered testing date.
Time since intake testing (months)
I
n
c
i
d
e
n
c
e
 
o
f
 
C
I
N
3
+
 
p
e
r
 
1
0
 
0
0
0
0 12 24 36 48 60 72
0
1000
2000
3000
4000
Cytology-/HPV-
Cytology-/HPV+
Cytology+/HPV-
Cytology+/HPV+
Fig1 |Kaplan-MeierplotsofcumulativeincidencerateforCIN3+
for women according to baseline test results in the first
72 months of follow-up in all seven countries
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Fig2 |Kaplan-MeierplotsofcumulativeincidencerateforCIN3+
for womenaccording tobaselinetestresultsinfirst 72months
of follow-up, excluding Denmark and Tübingen
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dence rate of CIN3+ by original baseline group
(cytology−/HPV−,c y t o l o g y −/HPV+, cytology+/
HPV−, and cytology+/HPV+) for each country, with
95% confidence intervals, using the non-parametric
Kaplan-Meier product limit estimator for
log(hazard).
23 Secondly, to determine whether lack of
homogeneity between the different studies in the joint
cohortinfluencedresultsweusedcomparativeanalysis
ofsystematicallydrawnsubsamplesofthejointcohort,
so called bootstrap analysis.
24 The bootstrap stratified
random subsample was constructed by drawing, with
replacement, firstly from studies and then from
individuals within studies. We constructed and ana-
lysed 1000 bootstrap replications in the same manner
as the original country specific analysis and used the
mean of these 1000 replicas as the pooled estimate of
the cumulative incidence rate corrected for hetero-
geneity, with 2.5 and 97.5 centiles as estimates for the
95% confidence interval. As a measure for hetero-
geneity, we compared the original cohort specific 95%
confidence intervals with those obtained from the
multilevel bootstrap. This can be transformed into an
estimate of the overdispersion parameter (or “scale”
parameter),where1pointstonoheterogeneityamong
the studies and >1 points to increasing levels of
heterogeneity.
2526 Thirdly, we calculated the test
performance indices for cytology alone, HPV test
alone, and cytology and HPV test combined (at least
one of the two positive). Because we did not have
complete data for all four original baseline groups, we
excluded studies from Denmark and Tübingen from
theseanalyses.Theseindiceswerecalculatedusing2×2
tables based on the cumulative incidence rate at
72 months forthe different baselinetest combinations,
weighted by the proportion (adjusted for heterogene-
ity) of each of these subgroups at baseline.
27 The 95%
confidence intervals around the indices were obtained
by bootstrapping.
25 All analyses used S-PLUS 6.0
Professional Release 1.
RESULTS
Out of 24295 women included in the pooled analyses,
381developedhistologicallyconfirmedCIN3+during
sixyears’offollow-up(table 2).Thepositivepredictive
value for future CIN3+ was highest among women
with abnormal cytology and positive HPV test at
baseline (cytology+/HPV+) (cumulative incidence
rate 34%, 95% confidence interval 26.8% to 45.4%)
(fig1).WomenwithnormalcytologybutpositiveHPV
test (cytology−/HPV+) had a continuously increasing
cumulativeincidencerateofCIN3+,eventuallyreach-
ing 10% (6.2% to 15.1%) after six years. Women with
abnormalcytologyandnegativeHPVtest(cytology+/
HPV−) had a cumulative incidence rate for CIN3+ of
2.7% (0.6% to 6.0%). Women with both normal
cytology and negative HPV test (cytology−/HPV−)
had a low risk of future CIN3+ (0.28%, 0.10% to
0.47%).Wecomparedthecumulativeincidencerateof
CIN3+afterbeingcytology−/HPV−withthatofCIN3
+ for normal cytology alone and negative HPV test
alone(fig2).Atsixyearsoffollow-up,therateofCIN3
+ was significantly lower among women negative for
HPV(0.27%,0.12%to0.45%)thanamongwomenwith
negative cytology results (0.97%, 0.53% to 1.34%). By
comparison, the rate of CIN3+ at the most commonly
recommended screening interval in Europe (three
years) was 0.51% (0.23% to 0.77%) for women with
negative cytology results and 0.12% (0.03% to 0.24%)
for womennegative forHPV. At five and four years of
follow-up, the rates were 0.25% (0.12% to 0.41%) and
0.19% (0.08% to 0.32%) for women negative for HPV
Table 2 |Numberofwomeninanalysis,andnumberwithcervicalintraepithelialneoplasia
grade3orcancer(CIN3+)diagnosedwithin6yearsofbaseline
Baseline group No at baseline*
No still in follow-up
No with CIN3+ After 60 months After 72 months
Cytology−/HPV− 21 060 7019 4571 32
Cytology−/HPV+ 1962 268 111 107
Cytology+/HPV− 436 89 46 10
Cytology+/HPV+ 837 67 40 232
Total 24 295 7443 4778 381
*With at least one cytology or histology follow-up.
Table 3 |Testcharacteristicsforcytology(95%CI)at72months,byage(years),excludingdatafromDenmarkandTübingen
Overall >49 35-49 <35 P* 30-34† <30† P‡
Negative at baseline 20 078 3380 10 308 6390 982 2080
CIN3+ 127 9 48 70 14 21
Positive at baseline 1273 161 557 555 111 330
CIN3+ 242 33 112 97 25 48
Sensitivity 0.599
(0.348 to 0.683)
0.760
(0.504 to 0.903)
0.641
(0.506 to 0.747)
0.431
(0.137 to 0.615)
0.034 0.642
(0.511 to 0.773)
0.524 (0.389 to
0.669)
0.268
Specificity 0.954
(0.930 to 0.977)
0.964
(0.960 to 0.970)
0.959
(0.940 to 0.979)
0.937
(0.891 to 0.974)
0.546 0.924
(0.915 to 0.934)
0.875 (0.864 to
0.884)
<0.001
NPV 0.990
(0.987 to 0.995)
0.997
(0.995 to 0.999)
0.993
(0.990 to 0.997)
0.979
(0.965 to 0.990)
0.008 0.981
(0.971 to 0.990)
0.975 (0.960 to
0.987)
0.479
PPV 0.211
(0.102 to 0.291)
0.198
(0.048 to 0.915)
0.227
(0.113 to 0.342)
0.200
(0.087 to 0.269)
0.924 0.296
(0.191 to 0.403)
0.160 (0.123 to
0.197)
0.021
CIN3+=cervical intraepithelial neoplasia grade 3 or cancer; NPV=negative predictive value; PPV=positive predictive value.
*P value for trend.
†As only studies in France and Spain contained women <30 with complete test data, data for women aged 30-34 and <30 as well as P value for trend are restricted to these cohorts only.
‡P value for trend.
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(0.39% to 0.98%) for women with negative cytology
results. There was little difference in rates for CIN3+
betweenwomenwithnegativeresultsonbothtestsand
women negative for HPV (fig 2). The rate for CIN3+
among women positive for HPV was lower than for
women with abnormal results on cytology but
increased continuously and gradually approached the
rate of women with positive results on cytology (fig 3).
Analysis with an alternative outcome definition that
included all high grade lesions (CIN grade 2 or worse;
CIN2+) showed essentially similar results but was
based on a higher number of cases (n=585). For
example, at six years of follow-up, the cumulative
incidence rate of CIN2+ was 0.67% (0.39% to 1.11%)
among womennegative for HPV and 1.76% (1.00% to
2.47%) among women with negative cytology results.
Theratesatthreeyearsoffollow-upwere0.19%(0.07%
to 0.38%) and 0.79% (0.43% to 1.16%), respectively.
As the prevalence of HPV infection is highly age
dependent and as cytological performance also varies
with age, we analysed positive and negative predictive
values, sensitivity, and specificity of the screening tests
stratified by age group (tables 3, 4, and 5). The
sensitivity and negative predictive value of cytology
improved with age (table 3). Both cytology (table 3)
and the HPV test (table 4) had higher specificity for
womenabove35yearsbutdidnotimproveanyfurther
among women above 49.
The seven studies included in the pooled analyses
had estimates of cumulative incidence rate for CIN3+
that were not significantly different among cytology−/
HPV−,c y t o l o g y −/HPV+, or cytology+/HPV−
women (scale parameters: 2.48, 1.80, 2.23; P values
0.14,0.36,0.1).ThecumulativeincidencerateofCIN3
+ amongwomenwith positivecytology and HPV test,
however, was clearly different between studies (scale
parameter 4.77; P=0.01) (fig 4).
DISCUSSION
Main findings and strengths
Using pooled data from seven HPV screening studies
in six European countries we estimated a cumulative
incidence rate for future histologically confirmed
CIN3+ during six years of follow-up. The uniformly
low rate among women with negative results on both
cytologyandHPVtestssuggeststhatdoublenegativity
confers a long lasting protective effect that is remark-
ably robust, considering that the participating studies
used several different types of HPV tests in several
different settings and in several different age groups.
The long lasting protective effect was similarly low in
women negative for HPV and women with negative
results on both tests.
That several studies in different settings in different
countriesandwithdifferentinfrastructureandintensity
of follow-up gave largely similar results is a strength of
thestudy,asitimpliesthatthedataaregeneralisableto
various settings. Similarly, that we studied the actual
cytological tests used in the different countries implies
thatthedataaregeneralisable—forexample,thelargest
studyinthejointcohort(France)usedthemostmodern
cytologytechnique(liquidbasedcytology)andseveral
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Fig4 |Comparisonofcumulativeincidencerate(95%confidence
interval)ofCIN3+at60monthsbycountryandbybaselinetest
results
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follow-up, excluding Denmark and Tübingen
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cytology as is used in organised programmes with a
documented preventive effect on cancer.
Consistency with other studies
Our results agree with the results from a US cohort of
20810 women that found that cytology−/HPV−
women had a cumulative incidence rate of CIN3+ of
0.16% after 45 months and 0.79% after 122 months.
7
Similarly,inaGermancohortof4034women,0.7%of
cytology−/HPV− women developed CIN3+ during
five years of follow-up
8 and in a Dutch cohort of 2810
women there was only one case of CIN3+ among
women with negative results on both tests during 4.
6 years of follow-up.
28
Limitations and other considerations
As expected, the HPV test was less specific than
cytology.Thehigherspecificityinwomenagedover35
suggests that restricting HPV testing to older women
wouldreduceoverdiagnosis.Withincreasinglengthof
follow-up, however, the cumulative incidence rate for
CIN3+ increased more among women positive for
HPV than among women with positive cytology
results. This implies that the problem of HPV based
screening resulting in increased overdiagnosis, with
women unnecessarily referred for clinical procedures,
is attenuated in evaluations with longer follow-up—
some of the HPV positivity that seems to be false
positivity in cross sectional evaluations will turn out to
be true, but earlier, detection of CIN3+.
Verification bias might overestimate the perfor-
mance of screening tests when only women with a
positive screening test result are referred for colpo-
scopy. Only some of the included studies performed
colposcopies in women with negative results on both
tests. It is, however, rare to diagnose CIN3+ by
colposcopy in such women
2930 and the fact that there
was limited variability between studies also suggests
that verification bias has not materially affected our
estimates.
Nevertheless,asassessmentoftheincidenceofCIN3
+ by baseline group during follow-up depends on the
intensity of screening our estimates should be
Table 5 |Testcharacteristicsforcytologyandhumanpapillomavirus(atleast1positive),(95%CI)at72months,byage(years),excludingdatafrom
DenmarkandTübingen
Overall >49 35-49 <35 P* 30-34† <30† P‡
Both negative at baseline 18 116 3084 9502 5530 850 1640
C I N 3 + 2 0 389 24
Positive at baseline 3235 457 1363 1415 243 770
CIN3+ 349 39 152 158 37 65
Sensitivity 0.921
(0.841 to 0.964)
0.897
(0.621 to 0.986)
0.935
(0.826 to 0.991)
0.993
(0.792 to 0.968)
0.695 0.954
(0.893 to 0.988)
0.845
(0.694 to 0.962)
0.113
Specificity 0.872
(0.810 to 0.925)
0.887
(0.850 to 0.934)
0.892
(0.837 to 0.931)
0.829
(0.729 to 0.914)
0.452 0.813
(0.800 to 0.830)
0.694
(0.666 to 0.714)
<0.001
NPV 0.998
(0.996 to 0.999)
0.999
(0.997 to 1.000)
0.999
(0.997 to 1.000)
0.994
(0.987 to 0.999)
0.126 0.997
(0.993 to 0.999)
0.988
(0.975 to 0.997)
0.097
PPV 0.147
(0.099 to 0.190)
0.089
(0.038 to 0.127)
0.144
(0.081 to 0.204)
0.178
(0.125 to 0.248)
0.071 0.224
(0.151 to 0.294)
0.122
(0.092 to 0.157)
0.016
CIN3+=cervical intraepithelial neoplasia grade 3 or cancer; NPV=negative predictive value; PPV=positive predictive value.
*P value for trend.
†As only studies in France and Spain contained women <30 with complete test data, data for women aged 30-34 and <30 as well as P value for trend are restricted to these cohorts only.
‡P value for trend.
Table 4 |Testcharacteristicsforhumanpapillomavirus(95%CI)at72months,byage(years),excludingdatafromDenmarkandTübingen
Overall >49 35-49 <35 P* 30-34† <30† P‡
Negative at baseline 18 552 3169 9740 5643 876 1683
CIN3+ 30 4 16 10 2 4
Positive at baseline 2799 372 1125 1.302 217 727
CIN3+ 339 38 144 157 37 65
Sensitivity 0.896
(0.796 to 0.949)
0.850
(0.452 to 0.986)
0.895
(0.749 to 0.971)
0.886
(0.778 to 0.966)
0.896 0.900
(0.785 to 0.965)
0.641
(0.433 to 0.873)
0.044
Specificity 0.893
(0.929 to 0.942)
0.912
(0.872 to 0.957)
0.914
(0.861 to 0.944)
0.847
(0.747 to 0.926)
0.405 0.921
(0.914 to 0.929)
0.873
(0.861 to 0.882)
<0.001
NPV 0.997
(0.996 to 0.999)
0.999
(0.995 to 1.000)
0.998
(0.996 to 1.000)
0.994
(0.988 to 0.999)
0.180 0.997
(0.993 to 0.999)
0.987
(0.974 to 0.997)
0.064
PPV 0.171
(0.127 to 0.214)
0.106
(0.040 to 0.149)
0.166
(0.100 to 0.219)
0.196
(0.141 to 0.271)
0.106 0.254
(0.179 to 0.333)
0.129
(0.097 to 0.168)
0.008
CIN3+=cervical intraepithelial neoplasia grade 3 or cancer; NPV=negative predictive value; PPV=positive predictive value.
*P value for trend.
†As only studies in France and Spain contained women <30 with complete test data, data for women aged 30-34 and <30 as well as P value for trend are restricted to these cohorts only.
‡P value for trend.
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31 We
included only women who had been screened at least
once during follow-up, and the follow-up time was
longerthantherecommendedscreeningintervalsinall
the included countries.
32
In one study (Spain), no action was taken because of
positive results of HPV tests at baseline whereas four
studies mandated extra testing or colposcopy, or both
(Sweden, Hannover, UK, and France). As we did not
include Denmark and Tübingen in the follow-up of
women with positive results on cytology or HPV tests,
our cumulative incidence rate of CIN3+ is almost
entirely based on active follow-up of HPV tests and
should reflect the outcome of active HPV based
screening strategies.
As prevalence of CIN3+ is associated with pre-
valence of HPV some heterogeneity between studies
might be explained by differences in prevalence of
HPV—for example, Spain has a low prevalence of
HPV.
22Anotherpossiblesourceofvariabilityisthefact
that the German, French, Danish, British, and Spanish
studiesusedhybridcaptureIIforHPVdetection,while
theSwedishstudyusedpolymerasechainreaction.The
agreementbetweenthetwoissubstantial,
3334andthere
was no obvious difference in results depending on the
HPV test used. The most obvious source of hetero-
geneity between countries was the variability in inter-
pretation of cervical smear tests, as the proportions of
positive cytology results ranged from 2% in Sweden to
over4%inHannoverandSpain,5%intheUK,and7%
in France; these differences cannot be entirely
explained by the observed differences in the preva-
lence of HPV.
Inconclusion,thesejointEuropeandatasuggestthat
screening intervals could safely be lengthened to six
yearsamongwomenwitha negativeresult onanHPV
test. This could at least partly compensate for the
increased referral rate resulting from HPV based
screening strategies.
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